Nxera Pharma Co., Ltd. (SOLTF)
OTCMKTS
· Delayed Price · Currency is USD
7.00
+1.09 (18.44%)
Jun 4, 2025, 10:08 AM EDT
Nxera Pharma Revenue
Nxera Pharma had revenue of 6.64B JPY in the quarter ending March 31, 2025, with 44.09% growth. This brings the company's revenue in the last twelve months to 30.87B, up 87.83% year-over-year. In the year 2024, Nxera Pharma had annual revenue of 28.84B with 125.87% growth.
Revenue (ttm)
30.87B JPY
Revenue Growth
+87.83%
P/S Ratio
2.79
Revenue / Employee
82.53M JPY
Employees
374
Market Cap
574.55M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.84B | 16.07B | 125.87% |
Dec 31, 2023 | 12.77B | -2.80B | -18.00% |
Dec 31, 2022 | 15.57B | -2.14B | -12.10% |
Dec 31, 2021 | 17.71B | 8.87B | 100.32% |
Dec 31, 2020 | 8.84B | -884.00M | -9.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Nxera Pharma News
- 5 weeks ago - Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 - GlobeNewsWire
- 5 weeks ago - Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia - GlobeNewsWire
- 5 weeks ago - Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations - GlobeNewsWire
- 2 months ago - Nxera Pharma Announces Appointments to its Executive Leadership Team - GlobeNewsWire
- 2 months ago - Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder - GlobeNewsWire
- 3 months ago - Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan - GlobeNewsWire
- 4 months ago - Nxera Pharma Proposes Changes to its Board of Directors - GlobeNewsWire
- 4 months ago - Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire